DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,258 filers reported holding DANAHER CORPORATION in Q3 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,846,392 | -2.2% | 7,390 | -2.2% | 0.58% | +0.3% |
Q1 2024 | $1,887,883 | +8.0% | 7,560 | -0.1% | 0.58% | +0.7% |
Q4 2023 | $1,747,662 | +12.6% | 7,564 | -5.6% | 0.58% | -0.2% |
Q3 2023 | $1,551,570 | -15.1% | 8,011 | +5.2% | 0.58% | -7.6% |
Q2 2023 | $1,826,880 | -3.1% | 7,612 | +1.7% | 0.63% | -4.4% |
Q1 2023 | $1,886,015 | +82947.8% | 7,483 | -12.5% | 0.66% | -17.3% |
Q4 2022 | $2,271 | -99.9% | 8,556 | -4.2% | 0.79% | -11.1% |
Q3 2022 | $2,307,000 | +1.1% | 8,931 | -0.7% | 0.89% | +4.4% |
Q2 2022 | $2,281,000 | -10.8% | 8,997 | +3.2% | 0.86% | +7.3% |
Q1 2022 | $2,557,000 | -13.2% | 8,717 | -2.6% | 0.80% | -8.0% |
Q4 2021 | $2,946,000 | +7.6% | 8,953 | -0.5% | 0.87% | +3.2% |
Q3 2021 | $2,739,000 | +10.7% | 8,998 | -2.5% | 0.84% | +12.3% |
Q2 2021 | $2,475,000 | +17.4% | 9,224 | -1.6% | 0.75% | +6.7% |
Q1 2021 | $2,109,000 | -2.5% | 9,374 | -3.7% | 0.70% | -15.8% |
Q4 2020 | $2,162,000 | +3.2% | 9,735 | +0.1% | 0.83% | -5.0% |
Q3 2020 | $2,094,000 | +41.7% | 9,725 | +16.3% | 0.88% | +36.3% |
Q2 2020 | $1,478,000 | +304.9% | 8,362 | +216.5% | 0.64% | +221.0% |
Q1 2020 | $365,000 | +5.2% | 2,642 | +16.7% | 0.20% | +36.1% |
Q4 2019 | $347,000 | +6.1% | 2,264 | -0.2% | 0.15% | +2.8% |
Q3 2019 | $327,000 | +51.4% | 2,269 | +49.9% | 0.14% | +30.0% |
Q2 2019 | $216,000 | +4.9% | 1,514 | -20.2% | 0.11% | +5.8% |
Q3 2018 | $206,000 | -0.5% | 1,897 | -7.5% | 0.10% | -5.5% |
Q2 2016 | $207,000 | -23.9% | 2,050 | -28.6% | 0.11% | -25.7% |
Q1 2016 | $272,000 | +32.0% | 2,870 | +29.1% | 0.15% | +25.4% |
Q4 2015 | $206,000 | -71.6% | 2,223 | -73.8% | 0.12% | -70.9% |
Q2 2015 | $726,000 | -8.0% | 8,479 | -8.7% | 0.40% | -5.6% |
Q1 2015 | $789,000 | -0.9% | 9,289 | 0.0% | 0.43% | -5.3% |
Q4 2014 | $796,000 | +21.7% | 9,289 | +7.8% | 0.45% | +17.1% |
Q3 2014 | $654,000 | -9.0% | 8,614 | -5.6% | 0.39% | -5.6% |
Q2 2014 | $719,000 | -1.2% | 9,129 | -6.0% | 0.41% | -7.9% |
Q1 2014 | $728,000 | -50.1% | 9,711 | -51.2% | 0.44% | -8.4% |
Q4 2013 | $1,459,000 | +111.4% | 19,920 | +100.0% | 0.49% | -1.6% |
Q3 2013 | $690,000 | +3.3% | 9,960 | -5.7% | 0.49% | -5.7% |
Q2 2013 | $668,000 | – | 10,560 | – | 0.52% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |